Navidea Biopharmaceuticals, Inc. NAVBQ

NAVBQ Company Overview

Navidea Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of precision diagnostic and immunotherapeutic products. The company historically operated in the molecular imaging and targeted diagnostics sector, with an emphasis on radiopharmaceutical agents used in oncology, inflammatory diseases, and precision medicine applications. Navidea became best known for developing Lymphoseek, a radiopharmaceutical imaging agent used for lymphatic mapping and sentinel lymph node identification in certain cancers.

The company’s primary historical revenue driver was related to licensing, royalties, and commercialization activities tied to its diagnostic imaging assets, particularly products associated with technetium Tc 99m tilmanocept. Over time, Navidea expanded its strategic focus toward macrophage-targeted imaging and therapeutic development through programs involving Manocept technology. The company has undergone substantial restructuring and financial distress in recent years, including bankruptcy-related proceedings associated with its publicly traded securities under the ticker NAVBQ. Public filings and corporate disclosures indicate that Navidea evolved from a broader diagnostic imaging enterprise into a more narrowly focused biotechnology platform centered on targeted immunodiagnostics and related intellectual property.